


WIRKUNG DER ADIPOSITAS-OPERATION AUF ERKRANKUNGEN IM ZUSAMMENHANG MIT ÜBERGEWICHT



REFERENZEN

1) Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000; 232:515–529.
 2) Sugerman HJ, Felton WL 3rd, Sismanis A, Kellum JM, DeMaria EJ, Sugerman EL. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg 1999; 229:634–640; discussion 640–642.
 3) Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242:610–617; discussion 618–620.
 4) Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238:467–484; discussion 84–85.
 5) Ghosh CK, Chatterjee S, Venkatesan S. Effect of laparoscopic ovarian surgery with or without Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1:77–80.
 6) Sugerman HJ, Sugerman EL, Wolfe I, Kellum JM, Schweitzer MA, DeMaria EJ. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease. Ann Surg 2001; 234:41–46.
 7) DeMaria EJ, Sugerman HJ, Kellum JM, Meadow JG, Wolfe LG. Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity. Ann Surg 2002; 235:640–645; discussion 645–647.
 8) Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240:416–423; discussion 423–424.
 9) Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y: 500 patients: technique and results, with 3–60 month follow-up. Obes Surg 2000; 10:233–239.

© 2019 Medtronic. Alle Rechte vorbehalten. Medtronic, das Medtronic-Logo und Further, Together sind Warenzeichen von Medtronic. Andere Marken sind Eigentum eines Unternehmens von Medtronic. 807250 – 05/2019

Medtronic
Further, Together